Founded in February 2013, PepVax, Inc. is developing Immunotherapy to help patients with Triple Negative Breast Cancer (TNBC) by targeting specific proteins called MAGE A on tumors using thier proprietary SMARTmid Technology. PepVax, Inc. is an early-stage biotechnology company developing novel immunotherapy biologics to treat various cancers. PepVax Inc's development methodology along with the patented SMARTmid technology allows for a universal candidate that localizes the treatment for increased efficacy, decreased adverse effects, and decreased cost.